Comparative Study Evaluating the Effectiveness of Oral Iron (Ferrous Bisglycinate) and Intravenous Iron (Ferric Hydroxide Saccharate Complex) in Management of Iron Deficiency Anemia in Pregnant Women.

More than 1.6 billion people, almost a quarter of the world’s population, are anemic. Despite considerable economic and scientific advancement during recent decades, there has been, at best, only marginal reduction in the global prevalence of anemia. The World Health Organization (WHO) estimates that worldwide, 42% of pregnant women, 30% of non-pregnant women (aged 15 to 50 years), 47% of preschool children (aged 0 to 5 years), and 12.7% of men older than 15 years are anemic 1. Iron deficiency is not the only cause of anemia, butalso other micronutrient deficiencies such as (zinc,copper, folic acid and vitamin B complex) are incorporated as a cause of anemia. Anemia, defined by low hemoglobin or hematocrit, which are commonly used to assess the severity of iron deficiency in pregnant women. Objective: The present study was designed to compare the efficacy and tolerability of oral iron preparationferrous bisglycinate elemental iron 27 mg and intravenous iron (Ferric hydroxide saccharate complex100 mg /Ampoule)in the prevention of iron deficiency (ID) and iron deficiency anemia (IDA) in pregnant women. Method: Descriptive case series. The study was carried out in the department of Obstetrics and Gynecology at Fayoum general hospital over a period of 6 months from 09-2014 to 03-2015. Cases with proven iron deficiency with Hb? 7gm% were included in the study. Total iron deficit was calculated using a standard formula. Target hemoglobin was 10gm %.The pregnant women (n=200) were divided into two groups of pregnant women (n=100). After 28 weeks of gestation, each group was treated with one type of iron. First group, ferrous bisglycinate 27 mg (Pharaferro 27), second group, Intravenous (IV) iron(Ferric hydroxide saccharate complex100 mg /Ampoule ) respectively. Follow-up was done for one month. Hemoglobin level (Hb), mean corpuscular volume (MCV), mean corpuscular hemoglobin concentration (MCHC), reticulocyte count (RC), and serum ferritin were assessed after four weeks. Adverse effects were monitored at end of evaluation period. Results: The two groups were comparable in terms of both anthropometric and biologicdata,distribution of cases by economic status showed non-significantincrease inHb, serum ferritin, MCH, MCHC was seen in all two groups a (p<0.05). Nausea, vomiting, epigastric pain did not significantly coexist with ferrous bisglycinategroup, while myalgia and allergic reaction were significantly noticed in IV iron when compared with oral iron. Conclusions: It can be concluded that oral ironPharaferro 27mg (ferrous bisglycinate, zinc , copper , folic acid and vitamin B complex ) is the same the result in restored iron stores and increase in Hb when compare between IV iron (Ferric hydroxide saccharate complex) so can be considered the best Effective medication with tolerable side effects for treatment as well as prevention of iron deficiency anemia during pregnancy.